Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced or Metastatic Breast Cancer: early-phase trial registry
1 of 4 indexed Advanced or Metastatic Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Advanced or Metastatic Breast Cancer: 4 US clinical trials tracked, 1 recruiting.
Advanced or Metastatic Breast Cancer is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Kind Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-or-metastatic-breast-cancer
OPEN 1 | RECR 25% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Advanced or Metastatic Breast Cancer lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced or Metastatic Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced or Metastatic Breast Cancer is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals
NCT05187832
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
AstraZeneca
NCT04494425
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Pfizer
NCT06105632
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
Novartis Pharmaceuticals
NCT02154776
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced or Metastatic Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced or Metastatic Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced or Metastatic Breast Cancer page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Advanced or Metastatic Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kind Pharmaceuticals sponsors the most Advanced or Metastatic Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Kind Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced or Metastatic Breast Cancer condition card totals 4 registered trials; most-linked intervention Buparlisib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.